SCHEMBL23489098

SCHEMBL23489098

CC(C)C(=O)N(C)CCN(C)C(=O)OCc1ccc(C(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ LMNA P02545 1/20 0.49
▸ RXRA P19793 1/20 0.42
▸ RXRB P28702 1/20 0.42
▸ IDO1 P14902 2/20 0.41
▸ EGFR P00533 1/20 0.41
▸ PRSS1 P07477 1/20 0.40
▸ TPSAB1 Q15661 1/20 0.40
▸ NPC1 O15118 4/20 0.40
▸ RAB9A P51151 4/20 0.40
▸ KDM4E B2RXH2 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ F13A1 P00488 1/20 0.36
▸ TGM2 P21980 1/20 0.36
▸ TGM1 P22735 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ FAAH O00519 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18102101 0.95 MEN1 (0.47) MEN1KMT2ALMNARXRARXRB
SCHEMBL25978782 0.89 MEN1 (0.48) MEN1KMT2ALMNARXRARXRB
SCHEMBL21348178 0.87 MEN1 (0.47) MEN1KMT2ALMNARXRARXRB
SCHEMBL25749404 0.86 MEN1 (0.45) MEN1KMT2ALMNARXRARXRB
SCHEMBL25749525 0.85 MEN1 (0.46) MEN1KMT2ALMNARXRARXRB
SCHEMBL25749532 0.85 LMNA (0.46) MEN1KMT2ALMNARXRARXRB
SCHEMBL12396671 0.84 F13A1 (0.42) MEN1KMT2ALMNAEGFRPRSS1
SCHEMBL25751042 0.84 MEN1 (0.45) MEN1KMT2ALMNARXRARXRB
SCHEMBL26553066 0.84 ESRRG (0.49) MEN1KMT2ALMNARXRARXRB
SCHEMBL13029063 0.83 F13A1 (0.41) MEN1KMT2ALMNAEGFRPRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230381323-A1 RELEASABLE CONJUGATES FISH & RICHARDSON PC 2023-11-30 — — US disclosed
US-20230381323-A1 RELEASABLE CONJUGATES FISH & RICHARDSON PC 2023-11-30 — — US disclosed
US-11786599-B2 Releasable conjugates QUIAPEG PHARMACEUTICALS AB (SE) 2023-10-17 — — US disclosed
US-11786599-B2 Releasable conjugates QUIAPEG PHARMACEUTICALS AB (SE) 2023-10-17 — — US disclosed
US-11685742-B2 Anti-tumor compound and preparation method and use thereof DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) 2023-06-27 — — US disclosed
US-11685742-B2 Anti-tumor compound and preparation method and use thereof DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) 2023-06-27 — — US disclosed
US-20220118055-A1 RELEASABLE GLP-1 CONJUGATES FISH & RICHARDSON PC 2022-04-21 — — US disclosed
US-20210170045-A1 RELEASABLE ANTIBODY CONJUGATES FISH & RICHARDSON PC 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170045-A1 RELEASABLE ANTIBODY CONJUGATES BCR, CD47, RNASE1 MEN1 775/4885KMT2A 2325/4885LMNA 3509/4885
US-20230381323-A1 RELEASABLE CONJUGATES GUSB, ABCB11, UGT2B7 MEN1 2694/4885KMT2A 4144/4885LMNA 2176/4885
US-11685742-B2 Anti-tumor compound and preparation method and use thereof RCC2, REN, VHL MEN1 6/4885KMT2A 3583/4885LMNA 1004/4885
US-11786599-B2 Releasable conjugates GUSB, ABCB11, UGT2B7 MEN1 2694/4885KMT2A 4144/4885LMNA 2176/4885
US-20220118055-A1 RELEASABLE GLP-1 CONJUGATES GLP1R, GIPR, IAPP MEN1 279/4885KMT2A 4392/4885LMNA 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback